- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00316472
The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients
Study Overview
Detailed Description
This is a prospective, randomized, double-blind, placebo-controlled crossover study comparing niacinamide versus placebo in the reduction of serum phosphorus in hemodialysis patients. A determination of baseline laboratory values (serum phosphorus, calcium, albumin, biPTH, uric acid, complete blood count (CBC), and an NMR lipid panel) will precede the administration of the study drugs. The study will span a period of 21 weeks during which phosphorus levels will be checked on a weekly basis. Phosphorus binder dose will remain unchanged unless for safety reasons. For the first 8 weeks of treatment, patients will be randomized to either placebo or niacinamide. Both medications will be administered with a starting dose of one capsule twice per day (BID). Niacinamide and placebo will be formulated in 250 mg capsules. Placebo will be packaged to resemble the study drug in all physical attributes. The dose of niacinamide or placebo will be increased to 500 mg (2 capsules) BID at week 3 and 750 mg (3 capsules) BID at week 5. If hypophosphatemia (< 3.5 mg/dl) is present, then titration will not occur and the previous dose will be continued. However, titration will resume in subsequent weeks if the serum phosphorus is greater than 3.5 mg/dl. After 8 weeks, patients will undergo a 2 week washout period, then crossover from treatment arm to placebo, or vice versa, at week 11.
At the beginning of week 11, patients will cross over to the other treatment arm (either placebo or niacinamide) at one capsule (250 mg) twice per day. Subsequent titration will occur at week 13 and week 15. The treatment phase will be completed at the end of week 18. A set of labs will be drawn at the start of week 19, followed by a two week washout period.
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years
- Capable of giving informed consent
- Duration of chronic hemodialysis > 90 days
- Dose of phosphorus binder(s) stable over previous 2 week period
- Serum Phosphorus > 4.9 mg/dL based on most recent laboratory data within 1 month of enrollment
Exclusion Criteria:
- Pregnancy
- Known liver disease
- Active peptic ulcer disease
- Treatment with carbamazepine
- Intolerance to niacinamide
- Current medication regimen including niacin or niacinamide-containing vitamins
- More than 1 missed hemodialysis session in the last 30 days
- Planned or expected surgical procedure in the next 4 months
- Patients in nursing homes or extended care facilities where administration of the study drug may not be appropriately given
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Primary Endpoint: The change in serum phosphorus after 8 weeks of niacinamide versus placebo.
|
Secondary Outcome Measures
Outcome Measure |
---|
Secondary endpoints: To assess the effects of niacinamide on calcium-phosphorus product, biointact parathyroid hormone levels (biPTH), and lipid profiles after 8 weeks of therapy.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Daniel W Coyne, M.D>, Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Phosphorus Metabolism Disorders
- Hyperphosphatemia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Antimetabolites
- Micronutrients
- Hypolipidemic Agents
- Lipid Regulating Agents
- Vitamins
- Vitamin B Complex
- Nicotinic Acids
- Niacinamide
- Niacin
Other Study ID Numbers
- HSC05-0958
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperphosphatemia
-
Taisho Pharmaceutical Co., Ltd.CompletedHyperphosphatemia Patients on HemodialysisJapan
-
Kissei Pharmaceutical Co., Ltd.CompletedHemodialysis Patients With HyperphosphatemiaJapan
-
Kyowa Kirin Korea Co., Ltd.RecruitingHyperphosphatemiaKorea, Republic of
-
Kyowa Kirin Co., Ltd.CompletedHyperphosphatemiaJapan
-
Kyowa Kirin Co., Ltd.CompletedHyperphosphatemiaJapan
-
BayerCompleted
-
Washington University School of MedicineCompletedHyperphosphatemiaUnited States
-
Fresenius Medical Care North AmericaRenal Research InstituteCompleted
-
BayerCompletedHyperphosphatemia | DialysisJapan
Clinical Trials on Niacinamide
-
Beth Israel Deaconess Medical CenterCompletedAcute Kidney InjuryUnited States
-
University of Split, School of MedicineRecruitingContact DermatitisCroatia
-
Mount Vernon Cancer Centre at Mount Vernon HospitalCompletedBladder CancerUnited Kingdom
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Women's College HospitalUniversity Health Network, Toronto; Canadian Institutes of Health Research... and other collaboratorsRecruitingCarcinoma, Squamous Cell | Carcinoma, Basal Cell | Keratinocyte Carcinoma | Non-melanoma Skin CancerCanada
-
Women's College HospitalCanadian Institutes of Health Research (CIHR); The Kidney Foundation of Canada and other collaboratorsActive, not recruitingCarcinoma, Squamous Cell | Carcinoma, Basal Cell | Non-melanoma Skin CancerCanada
-
University of LouisvilleCompletedProgressive Supranuclear PalsyUnited States
-
Beersheva Mental Health CenterSupported by a Hilton Family Foundation grant to; International Schizophrenia...Completed
-
Farmoquimica S.A.Medcin Instituto da PeleCompletedAtopic DermatitisBrazil
-
Indonesia UniversityCompletedContact Dermatitis of HandsIndonesia